Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...
LUND, SE / ACCESS Newswire / March 18, 2026 / Cantargia (STO:CANTA) today reported the presentation of new pre-clinical data ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell ...
The American Cancer Society (ACS) awarded its 2026 Medal of Honor—its highest scientific recognition—to Tyler Jacks, PhD, ...
Bolstered Cash Position Expected to Capitalize the Company’s Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data ...
A study highlights a gap in cancer prevention, showing men undergo genetic testing less often yet are more likely to carry ...
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this ...
7hon MSN
Combination treatment benefits patients with advanced breast cancer that has spread to the brain
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
Worse financial well-being in midlife and older age—and especially declines over time—are associated with lower memory scores ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results